Press-release for stocks in the health technology sector

Prices are updated after-hours

sector : Health technology

save search

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
IMMP | News | $2.23 -1.33% 61K

Health Technology

| 4.15% | O: 0.46% H: 0.0% C: 0.0%
imp761 institute research study

BioLife Solutions Announces the Divestiture of its Stirling Freezer Business
Published: 2024-04-18 (Crawled : 12:00) - prnewswire.com
BLFS S | $15.355 1.42% 110K

Health Technology

| -1.84% | O: -8.9% H: 0.0% C: 0.0%
business solutions

BiomX Announces the Appointment of Susan Blum to its Board of Directors
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
PHGE | $0.28 -0.04% 36K

Health Technology

| Email alert Add to watchlist

Quebec's INESSS recommends BEYFORTUS for the prevention of RSV for all infants 8 months of age and younger(1)
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
SNY | News | $45.56 -1.19% 910K

Health Technology

| -0.52% | O: -1.81% H: 0.0% C: 0.0%
beyfortus for rsv

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
CALT | $18.74 690

Health Technology

| -2.9% | O: 1.53% H: 0.0% C: 0.0%
nephropathy congress world nefecon trial therapeutics

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
ALDX 4 | $4.06 2.27% 98K

Health Technology

| -1.02% | O: 1.28% H: 0.0% C: 0.0%
day research therapeutics development

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $5.595 16.56% 2.4M

Health Technology

| -4.21% | O: 10.02% H: 0.0% C: 0.0%
bb-301 first positive biopharma for trial opmd study

Teleflex Announces First Quarter 2024 Earnings Conference Call Information
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
TFX | $208.45 0.07% 21K

Health Technology

| -0.46% | O: -0.77% H: 0.0% C: 0.0%
first conference

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
AGIO | $29.3 0.93% 59K

Health Technology

| -0.38% | O: 0.83% H: 0.0% C: 0.0%
first conference financial results

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
SWTX | $43.905 -0.47% 96K

Health Technology

| 1.58% | O: 0.79% H: 0.0% C: 0.0%
first report therapeutics financial results

Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
SNN | $24.025 0.44% 240K

Health Technology

| -0.25% | O: -0.4% H: 0.0% C: 0.0%

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
BNTC | $5.595 16.56% 2.4M

Health Technology

| -4.21% | O: 10.02% H: 0.0% C: 0.0%
million biopharma

Todays' Top-5
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
BPTH | $6.21 91.67% 58M

Health Technology

| -2.56% | O: 73.48% H: 0.0% C: 0.0%
bp1002 leukemia trial

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
OCUL | $6.6 -12.93% 2.6M

Health Technology

| -4.77% | O: -5.78% H: 0.0% C: 0.0%
ocular positive for topline diabetic

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
TLSA | $0.62 20.86% 310K

Health Technology

| -7.61% | O: 5.05% H: 0.0% C: 0.0%
life neurology foralumab sciences meeting imaging

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
TGTX | $14.42 4.34% 980K

Health Technology

| -1.64% | O: 0.25% H: 0.0% C: 0.0%
cd20 briumvi contract sclerosis for therapeutics

Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
Published: 2024-04-18 (Crawled : 10:00) - prnewswire.com
MS | News | $90.79 0.79% 1.7M

Finance